Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C6H9N3O3 |
| Molecular Weight | 171.154 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 1 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
N[C@@H](CCC(=O)C=[N+]=[N-])C(O)=O
InChI
InChIKey=YCWQAMGASJSUIP-YFKPBYRVSA-N
InChI=1S/C6H9N3O3/c7-5(6(11)12)2-1-4(10)3-9-8/h3,5H,1-2,7H2,(H,11,12)/t5-/m0/s1
| Molecular Formula | C6H9N3O3 |
| Molecular Weight | 171.154 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 1 |
| Optical Activity | UNSPECIFIED |
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Computational and experimental analysis identified 6-diazo-5-oxonorleucine as a potential agent for treating infection by Plasmodium falciparum. | 2013-12 |
|
| Antiviral effects of 6-diazo-5-oxo-L-norleucin on replication of herpes simplex virus type 1. | 1997-02 |
|
| Influence of twenty potentially antiviral substances on in vitro multiplication of hepatitis A virus. | 1986-03 |
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 17:33:26 GMT 2025
by
admin
on
Mon Mar 31 17:33:26 GMT 2025
|
| Record UNII |
03J0H273KZ
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
9087
Created by
admin on Mon Mar 31 17:33:26 GMT 2025 , Edited by admin on Mon Mar 31 17:33:26 GMT 2025
|
PRIMARY | |||
|
138889
Created by
admin on Mon Mar 31 17:33:26 GMT 2025 , Edited by admin on Mon Mar 31 17:33:26 GMT 2025
|
PRIMARY | |||
|
157-03-9
Created by
admin on Mon Mar 31 17:33:26 GMT 2025 , Edited by admin on Mon Mar 31 17:33:26 GMT 2025
|
PRIMARY | |||
|
6-DIAZO-5-OXO-L-NORLEUCINE
Created by
admin on Mon Mar 31 17:33:26 GMT 2025 , Edited by admin on Mon Mar 31 17:33:26 GMT 2025
|
PRIMARY | |||
|
C427
Created by
admin on Mon Mar 31 17:33:26 GMT 2025 , Edited by admin on Mon Mar 31 17:33:26 GMT 2025
|
PRIMARY | |||
|
300000041479
Created by
admin on Mon Mar 31 17:33:26 GMT 2025 , Edited by admin on Mon Mar 31 17:33:26 GMT 2025
|
PRIMARY | |||
|
m4275
Created by
admin on Mon Mar 31 17:33:26 GMT 2025 , Edited by admin on Mon Mar 31 17:33:26 GMT 2025
|
PRIMARY | Merck Index | ||
|
03J0H273KZ
Created by
admin on Mon Mar 31 17:33:26 GMT 2025 , Edited by admin on Mon Mar 31 17:33:26 GMT 2025
|
PRIMARY | |||
|
7365
Created by
admin on Mon Mar 31 17:33:26 GMT 2025 , Edited by admin on Mon Mar 31 17:33:26 GMT 2025
|
PRIMARY | |||
|
DTXSID501028846
Created by
admin on Mon Mar 31 17:33:26 GMT 2025 , Edited by admin on Mon Mar 31 17:33:26 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PRODRUG -> METABOLITE ACTIVE |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
Inhibitor of several enzymes that utilize glutamine as a substrate
|
